# Endovision Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endovision-co

- Industry: Medical Devices & Equipment
- Headquarters: Daegu, South Korea
- Website: www.endovision.co.kr/
- Total disclosed funding: $2.6M
- Latest round: Series A (Dec 31, 2020)
- Investors on record: 2

## About

Based in South Korea, Endovision Co., Ltd. specializes in the development and manufacturing of innovative medical devices, particularly focusing on biocompatible products designed for various medical applications.Endovision Co., Ltd. is dedicated to providing advanced medical solutions, having been established in 2013 in Daegu, South Korea. The company's founder has a history in the medical device sector, though specific details about prior ventures are unavailable. In March 2026,?Endovision Co., Ltd.?raised? KRW 1.5 billion in pre-IPO funding from returning investor NH Venture Investment. The company has completed four funding deals in total.Endovision specializes in the development and manufacturing of innovative medical devices, with a strong focus on biocompatible products such as their flagship KIOMER M3, a patented bio-polymer regenerative material. This product is designed using a proprietary chemical treatment process that enhances the properties of chitosan, resulting in a material that exhibits significant antibacterial, hemostatic, anti-inflammatory, and moisturizing effects. KIOMER M3 is particularly effective at reducing the expression of inflammatory cytokines in wound healing, adsorbing harmful ammonia molecules, and providing a strong hemostatic response due to its positive charge interacting with negatively charged red blood cells and platelets. Endovision's product offerings cater to various medical fields, including gynecology, orthopedics, and veterinary medicine, and are sold in both domestic and international markets, targeting hospitals, universities, and pharmaceutical companies.Endovision generates revenue through the direct sale of its medical products and devices, particularly the KIOMER M3 line, to hospitals and healthcare providers. The company employs a business-to-business (B2B) transaction model, engaging in partnerships and contracts with medical institutions and wholesalers, ensuring that its innovative solutions reach end-users effectively. Given the nature of the medical device industry, transactions typically involve bulk orders, where institutions procure significant quantities of products based on their clinical needs. The pricing structure for these products is aligned with the value delivered, reflecting their advanced technology and efficacy in medical applications. Endovision's commitment to innovation and quality positions its offerings favorably in the competitive healthcare market, contributing to its revenue growth and market presence.In January 2026, Endovision Co., Ltd. raised KRW 11.5 billion in PRE-IPO funding, which will be allocated towards product clinical trials and regulatory approvals. The company aims to launch new medical devices tailored to expanding markets, although specific product release dates and targeted geographic regions for expansion have not been disclosed, indicating a strategic focus on growth in the medical device sector.

## Funding rounds

- Series A, Dec 31, 2020, $2.6M — Korea Asset Investment Securities, We Ventures

## Investors

- Korea Asset Investment Securities (https://capitalatlas.ai/funds/korea-asset-investment-securities) — Series A
- We Ventures — Series A